Ultragenyx Pharmaceutical Inc. is wading into a complex and competitive area of gene therapy in a partnering deal with Solid Biosciences Inc. centered on Duchenne muscular dystrophy (DMD), but the firms are hoping that Ultragenyx’s manufacturing platform will give it an advantage over other DMD gene therapy programs.
The two companies announced the nearly $300m partnership and licensing deal 23 October, whereby Ultragenyx will contribute its HeLa producer cell line and adeno-associated virus 8 (AAV8) variants, receiving an exclusive license for any
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?